Hepatitis C–Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals | Gastroenterology | JAMA | JAMA Network
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
JAMA Network Home
JAMA
full text icon
Full Text
 contents icon
Contents
 figure icon
Figures /
Tables
 multimedia icon
Multimedia
 attach icon
Supplemental
Content
 references icon
References
 related icon
Related
 comments icon
Comments
1.
Meringer  H, Shibolet  O, Deutsch  L.  Hepatocellular carcinoma in the post-hepatitis C virus era: should we change the paradigm?   World J Gastroenterol. 2019;25(29):3929-3940. doi:10.3748/wjg.v25.i29.3929PubMedGoogle ScholarCrossref
2.
Chirikov  VV, Marx  SE, Manthena  SR, Strezewski  JP, Saab  S.  Development of a comprehensive dataset of hepatitis C patients and examination of disease epidemiology in the United States, 2013-2016.   Adv Ther. 2018;35(7):1087-1102. doi:10.1007/s12325-018-0721-1PubMedGoogle ScholarCrossref
3.
Belperio  PS, Chartier  M, Ross  DB, Alaigh  P, Shulkin  D.  Curing hepatitis c virus infection: best practices from the U.S. Department of Veterans Affairs.   Ann Intern Med. 2017;167(7):499-504. doi:10.7326/M17-1073PubMedGoogle ScholarCrossref
4.
Kramer  JR, Giordano  TP, Souchek  J, Richardson  P, Hwang  LY, El-Serag  HB.  The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C.   Am J Gastroenterol. 2005;100(1):56-63. doi:10.1111/j.1572-0241.2005.40670.xPubMedGoogle ScholarCrossref
5.
Davila  JA, Henderson  L, Kramer  JR,  et al.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.   Ann Intern Med. 2011;154(2):85-93. doi:10.7326/0003-4819-154-2-201101180-00006PubMedGoogle ScholarCrossref
6.
Ioannou  GN, Beste  LA, Green  PK,  et al.  Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores.   Gastroenterology. 2019;157(5):1264-1278. doi:10.1053/j.gastro.2019.07.033PubMedGoogle ScholarCrossref
This Issue
Views 3,334
Citations 2
View Metrics
Research Letter
September 8, 2020

Hepatitis C–Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals

Lauren A. Beste, MD, MSc1; Pamela Green, PhD2; Kristin Berry, PhD2; et al Pamela Belperio, PharmD3; George N. Ioannou, MD, MS4
Author Affiliations Article Information
  • 1General Medicine Service, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
  • 2Health Services Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
  • 3Patient Care Services/Population Health Services Office (10P4V), Department of Veterans Affairs, Washington, DC
  • 4Gastroenterology Service, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
JAMA. 2020;324(10):1003-1005. doi:10.1001/jama.2020.10121
visual abstract icon
Visual
Abstract
 editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia

Chronic hepatitis C virus (HCV) infection is an important cause of hepatocellular carcinoma (HCC) in the US. HCV eradication has been associated with a reduced risk of HCC.1 Despite effective direct-acting antiviral therapies that have been available since 2013, only 14% of patients with HCV in the US were cured as of 2016.2 In contrast, the Veterans Health Administration (VHA), the largest integrated health care system in the US, provides unrestricted access to HCV treatments and approximately 85% of its case load has achieved cure.3 We examined trends in HCC incidence within the VHA from 2002 to 2018, according to HCV status, to determine whether the burden of HCC changed following mass HCV treatment.

×